The Latest Breaking News from AbbVie

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

Early in 2025, dividend stocks are swinging back into favor as the Federal Reserve cuts interest rates.

This afternoon, the S&P 500 Index ($SPX ) (SPY ) is down -0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.71%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up -0.36%. Stocks are moving lower this afternoon, after the Dow Jones Industrials posted an...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.67%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.32%. March E-mini S&P futures (ESH25 ) are up by +0.71%, and March E-mini Nasdaq...

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.85%. March E-mini S&P futures (ESH25 ) are up by +0.42%, and March E-mini Nasdaq...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.

March S&P 500 E-Mini futures (ESH25) are up +0.46%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.73% this morning as solid earnings from Apple and Intel buoyed sentiment, while investors geared up for the release of the Federal Reserve’s first-line inflation gauge.